Russell Angus C. 4

What Happened Russell Angus C., a director of Lineage Cell Therapeutics (LCTX), was granted 125,000 derivative shares on July 1, 2026. The Form 4 lists the transaction as an award/acquisition (Code A) at $0.00 per share (total reported $0), indicating a compensatory grant rather than an open‑market purchase or sale. The award is a derivative instrument that will vest and become exercisable under the terms noted in the filing.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (appears timely).
• Transaction type/code: Grant/Award of a derivative security (Code A).
• Shares granted: 125,000; price reported: $0.00; total reported value: $0.
• Vesting/exercisability: Will vest and become exercisable on the earlier of July 1, 2027 or the issuer’s next annual meeting, subject to the reporting person’s continuous service (footnote F1).
• Shares owned after transaction: Not disclosed in the filing.
• No 10b5-1 plan, tax‑withholding, or late‑filing flags noted.

Context This is a compensatory award for a director (common practice) and not an immediate cash purchase or sale. As a derivative award, it may convert to exercisable rights or shares only if/when vesting and exercisability conditions are met. Such grants are routine and reflect company compensation rather than a direct trading signal.